What payment terms are accepted?

Accepted payment terms include LC and T/T.

What is the average lead time during peak season?

The peak season lead time is one month.

Which ports are nearest for export?

The nearest ports are Tianjin Xingang, Qingdao, and Shanghai.

Citicoline Sodium Injection 4ml: 0.5g Cardiovascular System Drug

Name: Citicoline Sodium Injection 4ml: 0.5g Cardiovascular System Drug
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 2020861372

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.50-1.50

20,000 Pieces

Sample price:US$1.00/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Suitable for

Elderly, Adult

Model NO.

4ml: 0.5g

State

Liquid

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Product Line

GMP Approval

Transport Package

Carton

Specification

4ml: 0.5g

Trademark

SHIMEN

Origin

Hebei

HS Code

3004909099

Production Capacity

1000000

Key features

Cerebral Circulation Improvement: Increases cerebral blood flow and promotes brain material metabolism for function recovery.

GMP Approved Production: Manufactured in strict accordance with GMP requirements using international advanced equipment.

Acute Brain Trauma Treatment: Specifically applied for acute brain trauma and consciousness disturbance after brain operations.

70-Year Brand History: Shijiazhuang No. 4 Pharmaceutical Co., Ltd. has a seventy-year business history in the industry.

Full Automation Control: Production and logistics processes feature full automation and information control.

Global Market Reach: Products exported to over 80 countries across Asia, Americas, Europe, Oceania, and Africa.

Top 100 Pharmaceutical Enterprise: Ranked among China's top 100 pharmaceutical industry enterprises for consecutive years.

Diverse Product Portfolio: Manufactures large volume injections, tablets, capsules, and small volume injections.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤9.24hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.